SEC Form 4 · accession 0000908662-16-000429
DYAX CORP · DYAX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Abbie Celniker
Other
Period of report
Jan 22, 2016
Accepted (ET)
Jan 22, 2016 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000907562
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $26.23 | Jan 22, 2016 | D | 50,000 | D | — | May 12, 2025 | Common Stock | 50,000 | 0 | D |
Explanation of responses
- F1Disposition of securities in connection with the acquisition of Dyax Corp. by Shire plc pursuant to an Agreement and Plan of Merger dated November 2, 2015 by and among Dyax Corp., Shire plc, Shire Pharmaceuticals International, and Parquet Courts, Inc. (the "Merger Agreement"). At the effective time of the merger, this option to purchase common stock, which vested in twelve substantially equal installments on each monthly anniversary of the date of grant (May 12, 2015), was cancelled and converted into only the right to receive (a) an amount in cash equal to the product of (i) the excess of (A) $37.30 over (B) the exercise price per share of such option, and (ii) the number of Shares underlying such Company Option and (b) one contractual contingent value right for each share subject to such option in accordance with and subject to a Contingent Value Rights Agreement to be entered into between Shire plc and a rights agent.